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In the United States, Inflammatory Bowel Disease (IBD) is the most common
reason patients are referred to gasteroenterologists.1 Due to the multitude of
symptoms, patients are often unaware that they suffer this condition. Because
of this complexity, IBD is often difficult to diagnose.2 Symptoms vary from
patientto patientandrangefrom:
➢ Cramps, Abdominal Pain
➢ Bloating, Diarrhea, Constipation
➢ Altered Gastrointestinal Motility
➢ Visceral Hypersensitivity
➢ Post Infectious Reactivity
➢ Carbohydrate Malabsorption
➢ Intestinal Inflammation
Fig 2. IBD Incidences from 1990-2016 Worldwide. 
Fig 1. (a) Two main types of IBD. (b) Microscopic Mucosal Architecture of 
the Healthy Intestinal Tissue (c) Microscopic Mucosal Architecture 
distortion of the inflamed tissue mucosal. 
According to the Center for Disease Control and Prevention, three million adults
in the United States are diagnosed with IBD as either Crohn’s disease or
Ulcerative Colitis.3 This statistic does not include pediatric patients and has
increased a million patients since 1999.2 Of these patients, most were likely born in
the United States, lived in suburban areas or in poverty and are Hispanic or non-
Hispanic Caucasians.3 Furthermore, three times as many women experience IBD
due to menstration.1 Although this disease is prevalent in 15% of primary care
cases1, pathogenesisof the disease is debated andunknown.
Fig 3. Step-up and top-down approach for patients with uncontrolled 
IBD.4
Fig 4. FTIR Analysis of Polymer-Drug Complexes.
Base on the literature, IBD impacts quality of life and does not have a medication
regimen that lacks major side effects. Thus, the proposed drug polymer complex
drug delivery system aims to reduce the inflammation of intestinal tissue in both
Crohn’s disease and Ulcerative Colitis. The optimization of the complex with the
integration of a stabilizer, polymer, and drug has been demonstrated by
nanoprecipitationmethodology.
The drug, polymer and solvent solution was added dropwise into a vial of
stabilizerand water underconstantstirring.
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Step 5: 
Surgery
Step 4: Biological 
therapy drugs such as 
Infliximab*
*Increase risk of rare 
cancers.
Step 3: Immune modifying 
drugs such as Azathioprine*
*Increase risk for rare 
lymphomas.
Step 2: Corticosteroids* to reduce 
inflammatory response
*Cause long term side effects.
Step 1A: Dietary restrictions or antibiotics
Step 1B: Autoinflammatory drug such as 
Mesalamine 
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The drug being formulated is a plant based metabolite and less carcinogenic 
than the medications listed above. 
The nanoprecipitate method was utilized to form a drug polymer complex.
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The future outlook for this project includes the development of a stable drug
delivery system and optimizing the drug release from the polymer through the
pH dissolution test, drug loading, mice studies, and drug coatings at different
pH of gastrointestinaltract for a specified period of time.
Scintillation vials were placed in front of a dark background to assess opacity. 
Vial 1 contains the drug and PVA as a stabilizer. 
Vial 2 contains the drug and P 127 as a stabilizer. 
Vial 3 contains the drug and P 127 as a stabilizer. 
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